97 related articles for article (PubMed ID: 2649005)
1. [Evaluation of chemotherapy of hematological malignancies].
Masaoka T
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):316-22. PubMed ID: 2649005
[TBL] [Abstract][Full Text] [Related]
2. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
3. [A phase II study of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) in patients with acute leukemia and myelodysplastic syndromes. Cooperative Study Group for PL-AC].
Kimura K
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2475-81. PubMed ID: 3619459
[TBL] [Abstract][Full Text] [Related]
4. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
Kimura K; Yamada K; Uzuka Y; Masaoka T; Hirano M; Ohno R; Ogawa M
Gan To Kagaku Ryoho; 1989 Jan; 16(1):123-30. PubMed ID: 2643392
[TBL] [Abstract][Full Text] [Related]
5. [Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
Tanaka I; Kobayashi T; Shirakawa S; Ikeda Y; Kobayashi M; Yamagata K; Ohta K; Ohno R; Yamada H; Yamada K
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):493-8. PubMed ID: 3859248
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
Kurzrock R; Cortes J; Kantarjian H
Semin Hematol; 2002 Oct; 39(4 Suppl 3):20-4. PubMed ID: 12447848
[TBL] [Abstract][Full Text] [Related]
7. [A clinical study of sixteen polycythemia vera cases--acute myeloblastic leukemia in patients with polycythemia vera].
Takeyama H; Shimokawa T; Yamada H; Watanabe E
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2833-7. PubMed ID: 7993124
[TBL] [Abstract][Full Text] [Related]
8. Methods for evaluating response to treatment in adult acute leukemia.
Freireich EJ
Blood Cells; 1983; 9(1):5-20. PubMed ID: 6344935
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera: diagnosis and treatment 2002.
Berlin NI
Expert Rev Anticancer Ther; 2002 Jun; 2(3):330-6. PubMed ID: 12113056
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
11. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic studies in 32 patients with myelodysplastic syndrome: insights to specific chromosomal abnormalities and prognosis.
Taniwaki M; Horiike S; Inazawa J; Nishida K; Misawa S; Takino T; Abe T
Jpn J Clin Oncol; 1987 Jun; 17(2):141-50. PubMed ID: 3613138
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
14. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
[TBL] [Abstract][Full Text] [Related]
15. Topotecan in the treatment of hematologic malignancies.
Beran M; Kantarjian H
Semin Hematol; 1998 Jul; 35(3 Suppl 4):26-31. PubMed ID: 9779879
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
17. Resistance to therapy of acute leukemia developing in the course of polycythemia vera.
Donovan PB; Landaw SA; Dresch C; Gartenhaus WS; Goldberg JD; Ellis JT; Loeb V; Perry MC; Petitt RM; Pisciotta AV; Silver RT; Spurr CL; Weinfeld A; Berk PD
Nouv Rev Fr Hematol (1978); 1981; 23(4):187-92. PubMed ID: 7312612
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
19. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia.
Betticher DC; Huxol H; Müller R; Speck B; Nissen C
Exp Hematol; 1993 Nov; 21(12):1517-21. PubMed ID: 8405233
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease.
Notario A; Rolandi ML; Mazzucchelli I
Haematologica; 1996; 81(3):261-4. PubMed ID: 8767533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
